AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22946484 — intervention group
Group type: COMPARATOR
Intervention: Mortality in SGS and AC (surgically treated vs non-surgically treated)
Number of subjects: 2034
Study 22946546 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil (50 mg daily) for 8 weeks
Number of subjects: 23
Study 22947029 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 866
Study 22948699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging
Number of subjects: 936
Study 22948699 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiography (ECG)
Number of subjects: 936
Study 22948699 — intervention group
Group type: COMPARATOR
Intervention: Recognized myocardial infarction (RMI)
Number of subjects: 936
Study 22948699 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognized myocardial infarction (UMI) by CMR
Number of subjects: 936
Study 22948699 — intervention group
Group type: COMPARATOR
Intervention: No myocardial infarction (MI)
Number of subjects: 936
Study 22948699 — intervention group
Group type: COMPARATOR
Intervention: Unrecognized myocardial infarction (UMI) by ECG
Number of subjects: 936
Study 22951194 — intervention group
Group type: EXPERIMENTAL
Intervention: faecal calprotectin (fCal)
Number of subjects: 93
Study 22951194 — intervention group
Group type: EXPERIMENTAL
Intervention: ileoscopy
Number of subjects: 93
Study 22951194 — intervention group
Group type: COMPARATOR
Intervention: small bowel imaging
Number of subjects: 93
Study 22951194 — intervention group
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Number of subjects: 93
Study 22951194 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE and CTE
Number of subjects: 93
Study 22951377 — intervention group
Group type: COMPARATOR
Intervention: Vastus medialis obliquus (VMO) EMD
Number of subjects: 26
Study 22951377 — intervention group
Group type: COMPARATOR
Intervention: Vastus lateralis (VL) EMD
Number of subjects: 26
Study 22951377 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of VMO and VL EMD
Number of subjects: 26
Study 22952183 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron intake (≥1.63 mg/d)
Number of subjects: 60895
Study 22952183 — intervention group
Group type: EXPERIMENTAL
Intervention: Total iron intake (≥15.09 mg/d)
Number of subjects: 60895
Study 22952183 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver intake (≥100 g/wk)
Number of subjects: 60895
Study 22952183 — intervention group
Group type: COMPARATOR
Intervention: Red and processed meats intake
Number of subjects: 60895
Study 22952794 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Nursing Care Plans (SNCP)
Number of subjects: 24124
Study 22952794 — intervention group
Group type: COMPARATOR
Intervention: Usual Nursing Care (UNC)
Number of subjects: 24124
Study 22953007 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to attendance for surgery
Number of subjects: 2591
Study 22953007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of surgery
Number of subjects: 2591
Study 22953007 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of how to access services
Number of subjects: 2591
Study 22953007 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic status
Number of subjects: 2591
Study 22953007 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering of TT surgery
Number of subjects: 2591
Study 22954507 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily in 28-day cycles
Number of subjects: 149
Study 22954507 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 149
Study 22954655 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (two doses of a killed whole-cell B-subunit cholera vaccine)
Number of subjects: 48278
Study 22954655 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect (herd) protection from the oral cholera vaccine
Number of subjects: 48278
Study 22955120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood serum (CBS) eye drops, 0.15 ng per eye per day epithelial growth factor, administered for 1 month.
Number of subjects: 30
Study 22955296 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22955317 — intervention group
Group type: EXPERIMENTAL
Intervention: CD11b(+)CD14(+)S100A9(+) cells
Number of subjects: 0
Study 22955317 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion of CD11b(+)CD14(+) cells in PBMC
Number of subjects: 0
Study 22955317 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CD11b(+)CD14(+) cells
Number of subjects: 0
Study 22955317 — intervention group
Group type: COMPARATOR
Intervention: Inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine hydrochloride
Number of subjects: 0
Study 22955317 — intervention group
Group type: COMPARATOR
Intervention: Arginase inhibitor N-hydroxy-nor-l-arginine (nor-NOHA)
Number of subjects: 0
Study 22955317 — intervention group
Group type: COMPARATOR
Intervention: Blocking antibodies for IL-4Rα(+) and IL-10
Number of subjects: 0
Study 22955317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of S100A9(+) cells
Number of subjects: 0
Study 22955317 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14(+)S100A9(+) inflammatory monocytes
Number of subjects: 0
Study 22955319 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 47
Study 22955319 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-13 stimulation
Number of subjects: 47
Study 22955319 — intervention group
Group type: COMPARATOR
Intervention: Steroid-naive asthma
Number of subjects: 47
Study 22955319 — intervention group
Group type: COMPARATOR
Intervention: Steroid-using asthma
Number of subjects: 47
Study 22955319 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 47
Study 22955430 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 200
Study 22955439 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 515
Study 22955439 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 515
Study 22955514 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alkylresorcinols (AR)
Number of subjects: 407
Study 22956609 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold laser burns with halved energy flux
Number of subjects: 10
Study 22956609 — intervention group
Group type: COMPARATOR
Intervention: Threshold power laser burns
Number of subjects: 10
Study 22956946 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided interaction
Number of subjects: 40
Study 22956946 — intervention group
Group type: COMPARATOR
Intervention: Unguided interaction
Number of subjects: 40
Study 22958032 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 22958032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia in preterm newborns with necrotizing enterocolitis (NEC) and multiple organ dysfunction syndrome (MODS)
Number of subjects: 0
Study 22958032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 0
Study 22958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Number of subjects: 36
Study 22958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 36
Study 22958075 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination and MRI studies
Number of subjects: 36
Study 22958075 — intervention group
Group type: EXPERIMENTAL
Intervention: CT myelography
Number of subjects: 36
Study 22958084 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated saline transcranial Doppler (TCD) monitoring
Number of subjects: 1103
Study 22958084 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of leukoaraiosis (LA)
Number of subjects: 1103
Study 22959186 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg per day)
Number of subjects: 49
Study 22959621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic load breakfast
Number of subjects: 34
Study 22959621 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic load breakfast
Number of subjects: 34
Study 22959621 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 34
Study 22960277 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonometer measurements of muscle tone, elasticity, and stiffness
Number of subjects: 61
Study 22960277 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonometer measurements of biceps
Number of subjects: 61
Study 22960277 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonometer measurements
Number of subjects: 61
Study 22960352 — intervention group
Group type: EXPERIMENTAL
Intervention: ab-paclitaxel 100mg/m² with bevacizumab 10mg/kg
Number of subjects: 48
Study 22960783 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy program
Number of subjects: 20
Study 22960888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell therapy (mean 80 million cells, CD-34 + mean 0.92 million)
Number of subjects: 11
Study 22960888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell therapy
Number of subjects: 11
Study 22961865 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective V(1a)-agonist Phe(2)-Orn(8)-Vasotocin (POV)
Number of subjects: 18
Study 22961865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed V(1a)-/V(2)-agonist AVP
Number of subjects: 18
Study 22961865 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 18
Study 22961962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of cardiac arrhythmias in acute neurovascular patients during the first 72 hours after admission.
Number of subjects: 501
Study 22961962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring during the first 24 hours after admission.
Number of subjects: 501
Study 22961962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of serious arrhythmic tachycardia.
Number of subjects: 501
Study 22961962 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of arrhythmias in relation to age and neurological deficits.
Number of subjects: 501
Study 22961962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring capabilities based on risk factors.
Number of subjects: 501
Study 22963265 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF Aβ1-42 ≤ 192 pG/mL
Number of subjects: 0
Study 22963265 — intervention group
Group type: COMPARATOR
Intervention: CSF Aβ1-42 > 192 pG/mL
Number of subjects: 0
Study 22963265 — intervention group
Group type: EXPERIMENTAL
Intervention: total-tau/Aβ1-42 > 0.39
Number of subjects: 0
Study 22963265 — intervention group
Group type: COMPARATOR
Intervention: total-tau/Aβ1-42 ≤ 0.39
Number of subjects: 0
Study 22963265 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with lumbar puncture
Number of subjects: 0
Study 22963265 — intervention group
Group type: COMPARATOR
Intervention: Individuals without lumbar puncture
Number of subjects: 0
Study 22964015 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO) with Ascorbic Acid
Number of subjects: 12
Study 22964741 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant observation
Number of subjects: 87
Study 22964741 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgical resection
Number of subjects: 87
Study 22964989 — intervention group
Group type: COMPARATOR
Intervention: High-resolution macular imaging using adaptive optics scanning laser ophthalmoscopy and spectral domain optical coherence tomography.
Number of subjects: 3
Study 22964989 — intervention group
Group type: COMPARATOR
Intervention: Best-corrected visual acuity assessment.
Number of subjects: 3
Study 22964989 — intervention group
Group type: COMPARATOR
Intervention: Kinetic and static perimetry and full-field electroretinography.
Number of subjects: 3
Study 22964989 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic sequencing of the CLRN1 gene.
Number of subjects: 3
Study 22965160 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 1
Study 22965160 — intervention group
Group type: COMPARATOR
Intervention: Leptin discontinuation
Number of subjects: 1
Study 22965568 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for clinically localized melanoma
Number of subjects: 100
Study 22965594 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle closure (PACS, PAC, PACG)
Number of subjects: 1426
Study 22965594 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1426
Study 22965594 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallower ACD
Number of subjects: 1426
Study 22965594 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter AL
Number of subjects: 1426
Study 22965964 — intervention group
Group type: EXPERIMENTAL
Intervention: SB1518 (100 to 600 mg/d)
Number of subjects: 34
Study 22966090 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with type 1 diabetes
Number of subjects: 22
Study 22966090 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 22966170 — intervention group
Group type: EXPERIMENTAL
Intervention: Short alleles (≤ 25 repeats) of HMOX1 gene promoter polymorphism
Number of subjects: 942
Study 22966170 — intervention group
Group type: COMPARATOR
Intervention: Longer alleles of HMOX1 gene promoter polymorphism
Number of subjects: 942
Study 22966170 — intervention group
Group type: EXPERIMENTAL
Intervention: HMOX1 gene promoter polymorphism
Number of subjects: 942
Study 22966847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors
Number of subjects: 0
Study 22966847 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocols
Number of subjects: 0
Study 22967195 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-purchase (POP) nutrition information intervention
Number of subjects: 224
Study 22967868 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.0% bevacizumab for 3 weeks
Number of subjects: 20
Study 22967996 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (240 mg) plus vinorelbine (25 mg/m2)
Number of subjects: 79
Study 22968145 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-OCT analysis in AMD eyes
Number of subjects: 467
Study 22968145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AMD)
Number of subjects: 467
Study 22968145 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal drusen associated with other foveal pathology
Number of subjects: 467
Study 22968145 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal hyperreflectivity over drusen
Number of subjects: 467
Study 22968466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub vascular neurologists using ResolutionMD
Number of subjects: 53
Study 22968742 — intervention group
Group type: EXPERIMENTAL
Intervention: COR-1 (10-240 mg, single i.v. administration)
Number of subjects: 50
Study 22968742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, single i.v. administration)
Number of subjects: 50
Study 22969103 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22969149 — intervention group
Group type: EXPERIMENTAL
Intervention: pH1N1 vaccine (revaccination)
Number of subjects: 40
Study 22969149 — intervention group
Group type: COMPARATOR
Intervention: pH1N1 vaccine (initial vaccination)
Number of subjects: 40
Study 22969149 — intervention group
Group type: COMPARATOR
Intervention: Control HCWs (no revaccination)
Number of subjects: 40
Study 22969149 — intervention group
Group type: EXPERIMENTAL
Intervention: pH1N1 vaccine (for LRs)
Number of subjects: 40
Study 22970121 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D
Number of subjects: 982
Study 22970121 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D in patients with TnT release
Number of subjects: 982
Study 22970121 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of 25(OH)D
Number of subjects: 982
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to preventive care recommendations
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation advice
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to smoking cessation program
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin-A1c screenings for diabetes
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin excretion test for kidney disease
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence rates for coronary artery disease, hypertension, and dyslipidemia
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at target for blood pressure
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at target for LDL-cholesterol levels
Number of subjects: 4931
Study 22970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes at target for hemoglobin-A1c
Number of subjects: 4931
Study 22971786 — intervention group
Group type: EXPERIMENTAL
Intervention: Daniel Fast with krill oil supplementation (2 g/day)
Number of subjects: 39
Study 22971786 — intervention group
Group type: COMPARATOR
Intervention: Daniel Fast with placebo supplementation (coconut oil; 2 g/day)
Number of subjects: 39
Study 22971786 — intervention group
Group type: EXPERIMENTAL
Intervention: Daniel Fast (combined data from both groups)
Number of subjects: 39
Study 22971949 — intervention group
Group type: EXPERIMENTAL
Intervention: OFDI with sampling rate of 0.125 mm
Number of subjects: 126
Study 22971949 — intervention group
Group type: EXPERIMENTAL
Intervention: OFDI with sampling rate of 1.0 mm
Number of subjects: 126
Study 22972437 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D (US weights)
Number of subjects: 118
Study 22972437 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI2 (Canadian weights)
Number of subjects: 118
Study 22972437 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3 (Canadian weights)
Number of subjects: 118
Study 22972437 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between instruments
Number of subjects: 118
Study 22972437 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility scores by depression severity
Number of subjects: 118
Study 22972437 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to general US population
Number of subjects: 118
Study 22972589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib-based combination therapy (with dacarbazine, docetaxel, temsirolimus, or erlotinib)
Number of subjects: 18
Study 22972589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib-based combination therapy
Number of subjects: 18
Study 22972589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib-containing regimens
Number of subjects: 18
Study 22973678 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance improvement intervention
Number of subjects: 7605
Study 22973678 — intervention group
Group type: COMPARATOR
Intervention: Baseline use of B-blockers and aldosterone antagonists
Number of subjects: 7605
Study 22973678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists and HF education
Number of subjects: 7605
Study 22973876 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha (activated) (DAA) at 50 ng/ml and 5 μg/ml
Number of subjects: 104
Study 22973876 — intervention group
Group type: COMPARATOR
Intervention: TNF alpha stimulation
Number of subjects: 104
Study 22973876 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment
Number of subjects: 104
Study 22974533 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FMISO dPET-CT and functional MRI combined with intensity modulated radiation therapy (IMRT)
Number of subjects: 15
Study 22974533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 15
Study 22974533 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FMISO dPET-CT and functional MRI
Number of subjects: 15
Study 22974830 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 0
Study 22975218 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 22975218 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study 22977195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² on day 1 and then 250 mg/m² weekly) in combination with docetaxel (75 mg/m² every 3 weeks or 35 mg/m² on days 1, 8, 15 every 4 weeks)
Number of subjects: 38
Study 22977195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 38
Study 22978540 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocervical decompression surgery
Number of subjects: 48
Study 22978748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (2.5, 5, 10 mg/day)
Number of subjects: 535
Study 22980297 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene Expression Score (GES)
Number of subjects: 1160
Study 22980297 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Perfusion Imaging (MPI)
Number of subjects: 1160
Study 22980297 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain symptoms
Number of subjects: 1160
Study 22980441 — intervention group
Group type: EXPERIMENTAL
Intervention: (177)Lu-cG250
Number of subjects: 23
Study 22980667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary video-assisted thoracoscopic surgery ultrasonography (VATS-US)
Number of subjects: 46
Study 22980667 — intervention group
Group type: COMPARATOR
Intervention: Standard VATS techniques
Number of subjects: 46
Study 22981498 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (20mg) three times every week
Number of subjects: 139
Study 22981532 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers identified by nurses
Number of subjects: 138
Study 22981957 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted health education or counseling
Number of subjects: 0
Study 22982655 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical local treatment (surgery or radiotherapy)
Number of subjects: 40
Study 22983573 — intervention group
Group type: EXPERIMENTAL
Intervention: High hemolytic component quartile
Number of subjects: 415
Study 22983573 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea therapy
Number of subjects: 415